Program: Oral and Poster Abstracts
Session: 802. Chemical Biology and Experimental Therapeutics: Poster I
Methods and Results: We designed specific BRD4 PROTACs, which contain a BRD4 binding moiety connected to an E3 ubiquitin ligase-recruiting moiety. In all ABC-DLBCL, and GCB-DLBCL cell lines tested, BRD4 PROTACs lead to potent (<10 nM), fast (<4hrs) and robust (>90%) degradation of BRD4. This degradation is accompanied by more pronounced and longer-lasting suppression of downstream signaling events, such as c-MYC, than small molecule inhibitors (JQ1 and OTX015) treatment. We confirmed that BRD4 degradation is E3 ligase-mediated and proteasome-dependent as both excessive E3 ligase binding ligand and proteasome inhibitors (MG132 and carfilzomib) were able to prevent PROTAC-induced BRD4 degradation. Most importantly, BRD4 PROTACs were more effective in inhibiting DLBCL cell proliferation (measured by CellTiter-Glo® Luminescent Cell Viability Assay) and inducing apoptosis (evaluated by caspase3/7 assay and PARP cleavage) compared to BRD4 inhibitors.
Conclusion: Hijacking E3 ubiquitin ligases, through PROTAC technology, is an innovative approach to achieve targeted, specific protein degradation. Such targeted degradation can provide important therapeutic advantages. Here, we demonstrated that BRD4 PROTACs lead to robust BRD4 downregulation, which results in better downstream signaling suppression, more pronounced inhibition of proliferation and induction of apoptosis compared to the effects of small molecule inhibitors. The results of on-going efficacy studies using a DLBCL tumor xenograft model will be presented at the meeting. Taken together, BRD4 degradation by PROTACs is a promising therapeutic strategy in DLBCL.
Disclosures: Lu: Arvinas, LLC: Employment , Equity Ownership . Qian: Arvinas, LLC: Employment , Equity Ownership . Raina: Arvinas, LLC: Employment , Equity Ownership . Altieri: Arvinas, LLC: Employment , Equity Ownership . Dong: Arvinas, LLC: Employment , Equity Ownership . Wang: Arvinas, LLC: Employment , Equity Ownership . Chen: Arvinas, LLC: Employment , Equity Ownership . Crew: Arvinas, LLC: Employment , Equity Ownership . Coleman: Arvinas, LLC: Employment , Equity Ownership . Crews: Arvinas, LLC: Employment , Equity Ownership . Winkler: Arvinas, LLC: Employment , Equity Ownership .
See more of: Chemical Biology and Experimental Therapeutics
See more of: Oral and Poster Abstracts
*signifies non-member of ASH